D. E. Shaw & Co., Inc. Annexon, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Annexon, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 81,411 shares of ANNX stock, worth $420,080. This represents 0.0% of its overall portfolio holdings.

Number of Shares

81,411

Holding current value

$420,080

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.49 - $7.2 $47,926 - $76,852	-10,674 Reduced 11.59%	81,411 $481,000
Q2 2024 Aug 14, 2024	SELL	$4.33 - $6.79 $1.24 Million - $1.95 Million	-287,169 Reduced 75.72%	92,085 $451,000
Q1 2024 May 15, 2024	BUY	$4.03 - $7.81 $1.53 Million - $2.96 Million	379,254 New	379,254 $2.72 Million
Q1 2023 May 15, 2023	SELL	$3.74 - $7.46 $192,135 - $383,242	-51,373 Reduced 65.44%	27,136 $104,000
Q4 2022 Feb 14, 2023	BUY	$4.56 - $6.61 $139,007 - $201,499	30,484 Added 63.48%	78,509 $405,000
Q3 2022 Nov 14, 2022	BUY	$3.75 - $6.63 $36,371 - $64,304	9,699 Added 25.31%	48,025 $297,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $4.06 $263,861 - $507,715	-125,053 Reduced 76.54%	38,326 $144,000
Q1 2022 May 16, 2022	BUY	$2.73 - $11.94 $446,024 - $1.95 Million	163,379 New	163,379 $446,000

Others Institutions Holding ANNX

# of Institutions

146

Shares Held

102M

Call Options Held

178K

Put Options Held

159K

Bain Capital Life Sciences Investors, LLC Boston, MA

8.45M
Shares

$43.6 Million
8.98% of portfolio
Satter Management Co., L.P.

7.41M
Shares

$38.2 Million
76.44% of portfolio
Bvf Inc San Francisco, CA

7M
Shares

$36.1 Million
1.32% of portfolio
Black Rock Inc. New York, NY

6.59M
Shares

$34 Million
0.0% of portfolio
Redmile Group, LLC San Francisco, CA

6.43M
Shares

$33.2 Million
2.49% of portfolio

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $246M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account